Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Psychic disorders and somnolence].

J L Houeto1, I Arnulf

  • 1Fédération de Neurologie, Centre d'Investigation Clinique, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

Revue Neurologique
|April 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial.

Revue neurologique·2023
Same author

Idiopathic hypersomnia and Kleine-Levin syndrome.

Revue neurologique·2023
Same author

Sleepiness in neurological disorders.

Revue neurologique·2023
Same author

Poor sleep quality and nocturnal home noninvasive ventilation: Prevalence, risk factors and impact.

Pulmonology·2023
Same author

[Potential teratogenicity of modafinil - Conflicting evidence, need for research].

Gynecologie, obstetrique, fertilite & senologie·2023
Same author

A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD.

NPJ Parkinson's disease·2020
Same journal

Macrophage inclusions in patients undergoing antisense oligonucleotide therapy for ALS or SMA: A retrospective and transversal study.

Revue neurologique·2026
Same journal

Geographic disparities in MRI features of ischemic stroke and small vessel disease: A comparative study between French Guiana and mainland France. Findings from the BECATOUR multicenter registry.

Revue neurologique·2026
Same journal

Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?

Revue neurologique·2026
Same journal

Neuro-Whipple presenting as autoimmune encephalitis.

Revue neurologique·2026
Same journal

Multimodal assessment of minimally conscious state and cognitive motor dissociation in neurocritical care: A critical review.

Revue neurologique·2026
Same journal

Development of a new episodic memory assessment tool (NEM): Preliminary data and clinical perspectives.

Revue neurologique·2026
See all related articles

Dopaminergic treatment for Parkinson's disease can cause hallucinations and sleepiness. Mesodiencephalic lesions may increase susceptibility to these neuropsychic side effects, impacting mood and behavior.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Context:

  • Dopaminergic agonists are commonly used in Parkinson's disease treatment.
  • Neuropsychiatric side effects, including hallucinations and excessive daytime sleepiness, are known complications.
  • Recent findings link narcolepsy-like sleep onset to dopaminergic-induced psychosis.

Purpose:

  • To explore the relationship between mesodiencephalic lesions and neuropsychic side effects of dopaminergic treatment.
  • To understand how Parkinson's disease pathology and antiparkinsonian drugs interact.
  • To highlight the neuro-psychic manifestations in Parkinson's disease.

Summary:

  • Dopaminergic treatment can induce visual hallucinations, psychosis, and somnolence, potentially requiring dose adjustment or alternative medications.

Related Experiment Videos

  • Mesodiencephalic lesions may predispose patients to these psychic effects, particularly when combined with dopaminergic therapy.
  • Parkinson's disease itself, coupled with treatment, can exacerbate mood disorders, impulse control issues, and addiction.

    • Impact:

    • Identifies potential mechanisms for neuropsychiatric complications in Parkinson's disease patients.
    • Emphasizes the complex interplay between disease, medication, and individual patient factors.
    • Suggests a need for careful monitoring of psychic well-being during dopaminergic therapy.